(Q33983927)

30 July 2017

1 reference

title

Lipodystrophy syndrome in HIV infection: what is it, what causes it and how can it be managed? (English)

1 reference

30 July 2017

G M Behrens

1

1 reference

30 July 2017

M Stoll

series ordinal

2

1 reference

30 July 2017

R E Schmidt

series ordinal

3

1 reference

30 July 2017

1 July 2000

1 reference

30 July 2017

1 reference

30 July 2017

23

1 reference

30 July 2017

57-76

1 reference

30 July 2017

1

1 reference

https://scigraph.springernature.com/pub.10.2165/00002018-200023010-00004

30 July 2017

0 references

cites work

Myocardial infarction in HIV-infected men receiving protease inhibitors

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00002018-200023010-00004

Insulin resistance in HIV protease inhibitor-associated diabetes

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00002018-200023010-00004

Protease inhibitors and adipocyte differentiation in cell culture.

21 January 2018

1 reference

12 December 2020

Generalized lipodystrophy, congenital and acquired (lipoatrophy).

1 reference

12 December 2020

Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome

1 reference

12 December 2020

Liposuction for protease-inhibitor-associated lipodystrophy

1 reference

12 December 2020

Striae formation in two HIV-positive persons receiving protease inhibitors

1 reference

12 December 2020

Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group.

1 reference

12 December 2020

A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors

1 reference

12 December 2020

Hyperlipidaemia following treatment with protease inhibitors in patients with HIV-1 infection

1 reference

12 December 2020

Gynaecomastia associated with saquinavir therapy

1 reference

12 December 2020

Bound leptin is regulated by tumour necrosis factor-alpha in HIV-infected patients: a potential mediator of wasting?

1 reference

12 December 2020

Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors.

1 reference

12 December 2020

Protease inhibitor-associated hyperinsulinaemia

1 reference

12 December 2020

Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance.

1 reference

12 December 2020

Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors

1 reference

12 December 2020

Ketoacidosis associated with protease inhibitor therapy

1 reference

12 December 2020

The effects of discontinuing stavudine therapy on clinical and metabolic abnormalities in patients suffering from lipodystrophy

1 reference

12 December 2020

A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy.

1 reference

12 December 2020

Vascular and lipid syndromes in selected HIV-infected patients

1 reference

12 December 2020

LMNA, encoding lamin A/C, is mutated in partial lipodystrophy.

1 reference

12 December 2020

Drug treatment of lipid disorders

1 reference

12 December 2020

Lipid lowering therapy in patients with HIV infection

1 reference

12 December 2020

Vascular complications associated with use of HIV protease inhibitors

1 reference

12 December 2020

Fasting hyperinsulinemia and increased waist-to-hip ratios in non-wasting individuals with AIDS.

1 reference

12 December 2020

Recombinant human growth hormone in patients with HIV-associated wasting. A randomized, placebo-controlled trial. Serostim Study Group.

1 reference

12 December 2020

Reversal of protease inhibitor-related visceral abdominal fat accumulation with recombinant human growth hormone

1 reference

12 December 2020

Dysregulation of insulin-like growth factors in a case of generalized acquired lipoatrophic diabetes mellitus (Lawrence Syndrome) connected with autoantibodies against adipocyte membranes

1 reference

12 December 2020

Fat distribution and metabolic changes in patients with HIV infection

1 reference

12 December 2020

The effect of protease inhibitors on weight and body composition in HIV-infected patients.

1 reference

12 December 2020

Body composition and endocrine function in women with acquired immunodeficiency syndrome wasting.

1 reference

12 December 2020

Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine.

1 reference

12 December 2020

Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy

1 reference

12 December 2020

Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients.

1 reference

12 December 2020

Coronary artery disease occurring with protease inhibitor therapy

1 reference

12 December 2020

Increased de novo hepatic lipogenesis in human immunodeficiency virus infection

1 reference

12 December 2020

Osteonecrosis of the femoral head in patients receiving HIV protease inhibitors

1 reference

12 December 2020

Effect of indinavir on HIV-related wasting

1 reference

12 December 2020

Visceral abdominal-fat accumulation associated with use of indinavir

1 reference

12 December 2020

Hypertrophy of the breasts in a patient treated with indinavir

1 reference

12 December 2020

A Gene for Congenital Generalized Lipodystrophy Maps to Human Chromosome 9q34

1 reference

12 December 2020

Syndrome of body fat redistribution in HIV-1-infected patients: relationships to cortisol and catecholamines

1 reference

12 December 2020

Relative influences of sex, race, environment, and HIV infection on body composition in adults

1 reference

12 December 2020

HIV protease inhibitors block human preadipocyte differentiation, but not via the PPARgamma/RXR heterodimer

1 reference

12 December 2020

Studies of body composition and fat distribution in HIV-infected and control subjects

1 reference

12 December 2020

Heterogeneity in adipose tissue metabolism: causes, implications and management of regional adiposity.

1 reference

12 December 2020

Lipodystrophy defined by a clinical score in HIV-infected men on highly active antiretroviral therapy: correlation between dyslipidaemia and steroid hormone alterations

1 reference

12 December 2020

Another case of breast hypertrophy in a patient treated with indinavir

1 reference

12 December 2020

Endocrine and metabolic evaluation of human immunodeficiency virus-infected patients with evidence of protease inhibitor-associated lipodystrophy

1 reference

12 December 2020

Clinical review 102: Type 2 diabetes mellitus: update on diagnosis, pathophysiology, and treatment

1 reference

12 December 2020

[Benign symmetrical lipomatosis ("peripheral lipodystrophy") during antiretroviral therapy of HIV infection]

1 reference

12 December 2020

Gemfibrozil effectively lowers protease inhibitor-associated hypertriglyceridemia in HIV-1-positive patients

1 reference

12 December 2020

Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study

1 reference

12 December 2020

Lipodystrophy in HIV-1-infected patients

1 reference

12 December 2020

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

1 reference

12 December 2020

Body weight changes with protease inhibitor treatment in undernourished HIV-infected patients.

1 reference

12 December 2020

Beneficial effects of protease inhibitors on body composition and energy expenditure: a comparison between HIV-infected and AIDS patients

1 reference

12 December 2020

Severe premature coronary artery disease with protease inhibitors

1 reference

12 December 2020

Protease inhibitors do not interfere with prohormone processing.

1 reference

12 December 2020

Circulating interferon-alpha levels and hypertriglyceridemia in the acquired immunodeficiency syndrome

1 reference

12 December 2020

Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects.

1 reference

12 December 2020

Dunnigan-Kobberling syndrome: an autosomal dominant form of partial lipodystrophy.

1 reference

12 December 2020

Fasting hyperinsulinemia and changes in regional body composition in human immunodeficiency virus-infected women

1 reference

12 December 2020

Images in clinical medicine. Lipodystrophy associated with an HIV-protease inhibitor

1 reference

12 December 2020

"Buffalo hump" in men with HIV-1 infection.

1 reference

12 December 2020

Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities

1 reference

12 December 2020

Protease inhibitor-induced lipodystrophy

1 reference

12 December 2020

Avascular necrosis in HIV infection

1 reference

12 December 2020

"Buffalo hump" in HIV-1 infection

1 reference

12 December 2020

Indinavir-associated lipodystrophy.

1 reference

12 December 2020

Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study

1 reference

12 December 2020

Gynaecomastia in a male patient during protease inhibitor treatment for acute HIV disease

1 reference

12 December 2020

Vascular complications associated with use of HIV protease inhibitors

1 reference

12 December 2020

A pilot study of exercise training to reduce trunk fat in adults with HIV-associated fat redistribution

1 reference

12 December 2020

Hypertriglyceridemia in the acquired immunodeficiency syndrome.

1 reference

12 December 2020

Marked hyperlipidaemia on ritonavir therapy

1 reference

12 December 2020

HIV-protease inhibitors

1 reference

12 December 2020

Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy

1 reference

12 December 2020

Early lipodystrophy occurring during post-exposure prophylaxis

1 reference

12 December 2020

Severe diabetes associated with protease inhibitor therapy

1 reference

12 December 2020

Type 2 diabetes in association with HIV-1 protease inhibitors in HIV-infected patients

1 reference

12 December 2020

Fat accumulation and HIV-1 protease inhibitors

1 reference

12 December 2020

Regional adiposity and morbidity

1 reference

12 December 2020

Leptin levels, beta-cell function, and insulin sensitivity in families with congenital and acquired generalized lipoatropic diabetes

1 reference

12 December 2020

Barraquer-Simons syndrome (with sensorineural deafness): a contribution to the differential diagnosis of lipodystrophy syndromes.

1 reference

12 December 2020

Development of cervical fat pads following therapy with human immunodeficiency virus type 1 protease inhibitors.

1 reference

12 December 2020

HIV-protease inhibitors

1 reference

12 December 2020

Subcutaneous adipocyte apoptosis in HIV-1 protease inhibitor-associated lipodystrophy

1 reference

12 December 2020

Increased soft tissue in the posterior cervical and upper back area of patients on HIV-1 protease inhibitors

1 reference

12 December 2020

Vascular complications associated with use of HIV protease inhibitors

1 reference

12 December 2020

Benign symmetric lipomatosis associated with protease inhibitors

1 reference

12 December 2020

Pseudo-Cushing's syndrome in human immunodeficiency virus-infected patients

1 reference

12 December 2020

Lipid evaluation in HIV-1-positive patients treated with protease inhibitors

1 reference

12 December 2020

Protease inhibitors, diabetes mellitus and blood lipids

1 reference

12 December 2020

Treatments for wasting in patients with the acquired immunodeficiency syndrome

1 reference

12 December 2020

Insulin sensitivity and insulin clearance in human immunodeficiency virus-infected men

1 reference

12 December 2020

Effects of metformin on insulin resistance and central adiposity in patients receiving effective protease inhibitor therapy

1 reference

12 December 2020

Highly active antiretroviral therapy

1 reference

12 December 2020

Increasing morbidity from myocardial infarction during HIV protease inhibitor treatment?

1 reference

12 December 2020

Partial lipodystrophy, mesangiocapillary glomerulonephritis, and complement dysregulation. An autoimmune phenomenon

1 reference

12 December 2020

Is treatment with ritonavir a risk factor for myocardial infarction in HIV-infected patients?

1 reference

12 December 2020

Disorders of fat distribution in HIV infection

1 reference

12 December 2020

Protease inhibitor-associated hyperglycaemia

1 reference

12 December 2020

Diabetes, insulin resistance and dyslipidaemia in lipodystrophic HIV-infected patients on highly active antiretroviral therapy (HAART).

1 reference

12 December 2020

Lipodystrophy in patients naive to HIV protease inhibitors

1 reference

12 December 2020

New-onset diabetes mellitus associated with use of protease inhibitor

1 reference

12 December 2020

Abnormal fat distribution and use of protease inhibitors

1 reference

12 December 2020

Anabolic effects of recombinant human growth hormone in patients with wasting associated with human immunodeficiency virus infection

1 reference

12 December 2020

Fat distribution in HIV-infected patients reporting truncal enlargement quantified by whole-body magnetic resonance imaging

1 reference

12 December 2020

Localized adipose tissue hypertrophy in patients receiving human immunodeficiency virus protease inhibitors

1 reference

12 December 2020

Decreased plasma concentrations of HDL cholesterol in HIV-infected individuals are associated with immune activation

1 reference

12 December 2020

New-onset diabetes mellitus associated with protease inhibitor therapy in an HIV-positive patient: case report and review.

1 reference

12 December 2020

Abnormal body-fat distribution in HIV-1-infected children on antiretrovirals

1 reference

12 December 2020

Extremely low values of serum leptin in children with congenital generalized lipoatrophy

1 reference

12 December 2020

Hyperlipidemia associated with protease inhibitor therapy

1 reference

12 December 2020

Vascular complications associated with use of HIV protease inhibitors

1 reference

12 December 2020

Inducible inactivation of hepatic LRP gene by cre-mediated recombination confirms role of LRP in clearance of chylomicron remnants

1 reference

12 December 2020

Abnormal fat distribution and use of protease inhibitors

1 reference

12 December 2020

Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study.

1 reference

12 December 2020

Changes in body habitus and serum lipid abnormalities in HIV-positive women on highly active antiretroviral therapy (HAART).

1 reference

12 December 2020

Monogenic disorders of obesity and body fat distribution.

1 reference

12 December 2020

Serum lipid concentration with reference to the clinical and immunological status of HIV infected men

1 reference

12 December 2020

Weight gain associated with protease inhibitor therapy in HIV-infected patients.

1 reference

12 December 2020

Short-term progressive resistance training increases strength and lean body mass in adults infected with human immunodeficiency virus

1 reference

12 December 2020

Lipodystrophy associated with nevirapine-containing antiretroviral therapies.

1 reference

12 December 2020

Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway

1 reference

12 December 2020

Mitochondrial toxicity of antiviral drugs

1 reference

12 December 2020

Suction-assisted lipectomy for lipodystrophy syndromes attributed to HIV-protease inhibitor use.

1 reference

12 December 2020

Hyperlipidemia under treatment with proteinase inhibitors

1 reference

12 December 2020

Hypocholesterolemia is associated with immune dysfunction in early human immunodeficiency virus-1 infection

1 reference

12 December 2020

Recombinant human growth hormone improves the fat redistribution syndrome (lipodystrophy) in patients with HIV.

1 reference

12 December 2020

ApoE genotype and protease-inhibitor-associated hyperlipidaemia

1 reference

12 December 2020

Familial partial lipodystrophy: two types of an X linked dominant syndrome, lethal in the hemizygous state

1 reference

12 December 2020

Elevated resting energy expenditure among HIV-seropositive persons receiving highly active antiretroviral therapy

1 reference

12 December 2020

Lipodystrophy in HIV-1-infected patients

1 reference

12 December 2020

A gene for congenital generalized lipodystrophy maps to human chromosome 9q34.

1 reference

12 December 2020

10.2165/00002018-200023010-00004

Identifiers

DOI

1 reference

Dimensions Publication ID

30 July 2017

0 references

1 reference